A new guideline is coming! The AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett’s Esophagus and Related Neoplasia will be published in Spring 2024.
Barrett’s esophagus is the precursor to esophageal adenocarcinoma. Endoscopic eradication therapy can be effective in eradicating Barrett’s esophagus and related neoplasia, but has greater risk of harms and resource use than surveillance endoscopy. This guideline provides evidence-based practice recommendations to guide the use of endoscopic eradication therapy in Barrett’s esophagus and related neoplasia.
As part of our guideline development process, we invite you to review this new guideline and share feedback during the public comment period.
Submit your comments by March 1, 2024.
Guideline documents for review
About the public comment period
AGA develops clinical practice guidelines using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, which provides a common, sensible and transparent approach to grading the quality of evidence and strength of recommendations, and uses the best practices outlined by the Institute of Medicine.
The public comment period is an integral part of AGA’s guideline development process. It allows AGA members and key stakeholders to review and comment on upcoming guidelines and their accompanying technical reviews.
Once an AGA guideline panel releases the drafts for public comment, identified stakeholders are alerted and submit their comments through an online survey. After the period ends, the guideline panel reviews and responds to the comments within two weeks. Revisions to the draft documents are at the discretion of the panel, but all comments will be considered and responses internally documented.
To see previously published guidelines, visit AGA’s clinical guidance library.
